Ind-Swift
Ind-Swift Laboratories Ltd, commonly referred to as Ind-Swift, is a prominent player in the pharmaceutical industry, headquartered in India. Established in 1986, the company has made significant strides in the development and manufacturing of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. With a strong operational presence across various regions, Ind-Swift is recognised for its commitment to quality and innovation. The company’s core offerings include a wide array of generic medications, which are distinguished by their adherence to stringent quality standards and regulatory compliance. Ind-Swift has achieved notable milestones, including certifications from major global regulatory bodies, solidifying its position as a trusted supplier in the competitive pharmaceutical landscape. Through its dedication to research and development, Ind-Swift continues to enhance its market presence and contribute to the healthcare sector.
DitchCarbon Score
How does Ind-Swift's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ind-Swift's score of 16 is lower than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ind-Swift's reported carbon emissions
Ind-Swift, headquartered in India, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Ind-Swift has not inherited any emissions data from a parent company, nor does it have any commitments to the Science Based Targets initiative (SBTi) or other climate initiatives. This lack of data and commitments suggests that Ind-Swift may need to enhance its climate strategy to align with industry standards and expectations for carbon emissions reduction. In the context of the pharmaceutical industry, where sustainability is increasingly important, Ind-Swift's absence of emissions reporting and reduction initiatives may impact its competitive positioning and stakeholder perceptions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ind-Swift is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
